Mobile

An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen A...

Update Il y a 5 ans
Reference: EUCTR2007-006055-39

An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Ablation Therapy

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To demonstrate efficacy of degarelix in achieving and maintaining testosterone suppression at castrate levels (≤0.5 ng/mL) during one year of treatment in prostate cancer patients.

Inclusion criteria

  • Prostate cancer

Links